Role of IL-1 and potential therapies in multiple sclerosis

Drug Discovery Today: Therapeutic Strategies

Volumn 4, Issue 1, 2007, Pages 19-24

  Warabi, Yoko ^a,b  

^a TOKYO METROPOLITAN NEUROLOGICAL HOSPITAL   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; APTAMER; ATORVASTATIN; BETA INTERFERON; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HERPESVIRUS VECTOR; IGURATIMOD; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; INTERLEUKIN 6; METHOTREXATE; METHYLPREDNISOLONE; OMEGA 3 FATTY ACID; PLACEBO; PRALNACASAN; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 765;

ACUTE DISEASE; ALLERGIC ENCEPHALOMYELITIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; GENE THERAPY; HUMAN; IMMUNOPATHOGENESIS; INFECTION; INFLAMMATION; INJECTION SITE REACTION; LOADING DRUG DOSE; LYMPHOMA; MAINTENANCE THERAPY; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUTROPENIA; NONHUMAN; PLASMAPHERESIS; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; STROKE; VIRAL GENE DELIVERY SYSTEM;

EID: 37249073916     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2007.08.006     Document Type: Review

References (38)

1. Matsumoto Y., et al. Complementarity-determining region 3 spectratyping analysis of the TCR repertoire in multiple sclerosis. J. Immunol. 170 (2003) 4846-4853
2. Gao W., et al. Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J. Immunol. 170 (2003) 107-113
3. Touzani O., et al. Potential mechanisms of interleukin-1 involvement in cerebral ischaemia. J. Neuroimmunol. 100 (1999) 203-215
4. Lemke R., et al. Differential injury-dependent glial expression of interleukins-1 alpha, beta, and interleukin-6 in rat brain. Glia 27 (1999) 75-87
5. Sims J.E., et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 241 (1988) 585-589
6. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147
7. Basu A., et al. The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. J. Neurosci. 22 (2002) 6071-6082
8. Moynagh P.N. The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain. J. Anat. 207 (2005) 265-269
9. Pinteaux E., et al. Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia. Glia 53 (2006) 551-556
10. Furlan R., et al. HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther. 14 (2007) 93-98
11. So A., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9 (2007) R28
12. Larsen C.M., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356 (2007) 1517-1526
13. Gartlehner G., et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metanalysis. J. Rheumatol. 33 (2006) 2398-2408
14. Boutin H., et al. Role of IL-1alpha and IL-1beta in ischemic brain damage. J. Neurosci. 21 (2001) 5528-5534
15. Emsley H.C., et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry 76 (2005) 1366-1372
16. Jacobs C.A., et al. Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. J. Immunol. 146 (1991) 2983-2989
17. Furlan R., et al. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J. Immunol. 163 (1999) 2403-2409
18. Bauer J., et al. Demonstration of interleukin-1 beta in Lewis rat brain during experimental allergic encephalomyelitis by immunocytochemistry at the light and ultra structural level. J. Neuroimmunol. 48 (1993) 13-21
19. Martin D., and Near S.L. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J. Neuroimmunol. 61 (1995) 241-245
20. Badovinac V., et al. Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J. Neuroimmunol. 85 (1998) 87-95
21. Aikawa Y., et al. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis. J. Neuroimmunol. 89 (1998) 35-42
22. Schrijver H.M., et al. Interleukin (IL)-1 gene polymorphisms: relevance of disease severity associated alleles with IL-1beta and IL-1ra production in multiple sclerosis. Mediators. Inflamm. 12 (2003) 89-94
23. Economides A.N., et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 9 (2003) 47-52
24. Paszkowski A.S., et al. Therapeutic application of caspase 1/interleukin-1beta-converting enzyme inhibitor decreases the death rate in severe acute experimental pancreatitis. Ann. Surg. 235 (2002) 68-76
25. Messerli S.M., et al. A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia 6 (2004) 95-105
26. Ravizza T., et al. Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy. Epilepsia 47 (2006) 1160-1168
27. Brodsky M., et al. The synthetic tellurium compound, AS101, is a novel inhibitor of IL-1beta converting enzyme. J. Interferon. Cytokine Res. 27 (2007) 453-462
28. Siegmund B., et al. IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13249-13254
29. Ferrari D., et al. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol. 176 (2006) 3877-3883
30. Sciacca F.L., et al. Induction of IL-1 receptor antagonist by interferon beta: implication for the treatment of multiple sclerosis. J. Neurovirol. 6 Suppl. 2 (2000) S33-S37
31. Pannu R., et al. Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats. J. Neurosci. Res. 79 (2005) 340-350
32. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 21 (2002) 495-505
33. Wingerchuk D.M., et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53 (1999) 1107-1114
34. Lennon V.A., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364 (2004) 2106-2112
35. Lennon V.A., et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202 (2005) 473-477
36. Warabi Y., et al. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J. Neurol. Sci. 252 (2007) 57-61
37. Misu T., et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130 Pt 5 (2007) 1224-1234
38. Warabi Y., et al. Characterization of the T cell receptor repertoire in the Japanese neuromyelitis optica: T cell activity is up-regulated compared to multiple sclerosis. J. Neurol. Sci. 249 (2006) 145-152